HomeInsightsStock Comparison

Bharat Immunological Biological Corporation Ltd vs Cohance Lifesciences Ltd Stock Comparison

Bharat Immunological Biological Corporation Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: Jun 01, 2025

Key Highlights

  • The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 25.56 as of 30 May 15:30.
  • The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Suven Pharmaceuticals Ltd changed from ₹ 2564 crore on March 2020 to ₹ 17223 crore on March 2024 . This represents a CAGR of 46.37% over 5 years.
  • The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 412.59 crore as compare to the Dec '24 revenue of ₹ 322.86 crore. This represent the growth of 27.79%.
  • The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Suven Pharmaceuticals Ltd for the Mar '25 is ₹ 84.13 crore as compare to the Dec '24 ebitda of ₹ 133.41 crore. This represent the decline of -36.94%.
  • The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Suven Pharmaceuticals Ltd changed from ₹ 120.59 crore to ₹ 38.73 crore over 8 quarters. This represents a CAGR of -43.33% .
  • The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Suven Pharmaceuticals Ltd changed from 23.57 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bharat Immunological & Biological Corporation Ltd

  • The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
  • BIBCOL was incorporated in 1989.
  • The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
  • BIBCL installed a plant of 100 mln units.
  • Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
  • The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

Bharat Immunological & Biological Corporation Ltd News Hub

News

Bharat Immunological & Biological Corporation Ltd leads losers in 'B' group

Relicab Cable Manufacturing Ltd, Precision Wires India Ltd, Brainbees Solutions Ltd and Fl...

Read more

08 Jan 2025 14:45

News

Bharat Immunological & Biological Corporation Ltd leads gainers in 'B' group

Bodhi Tree Multimedia Ltd, Mangal Credit & Fincorp Ltd, Innovana Thinklabs Ltd and Bartron...

Read more

06 Jan 2025 12:15

News

Bharat Immunological & Biolog.Corp. to hold board meeting

Bharat Immunological & Biolog.Corp. will hold a meeting of the Board of Directors of the C...

Read more

10 Aug 2024 17:28

News

Bharat Immunological & Biolog.Corp. announces board meeting date

Bharat Immunological & Biolog.Corp. will hold a meeting of the Board of Directors of the C...

Read more

01 Mar 2024 10:22

News

Bharat Immunological & Biolog.Corp. to convene AGM

Bharat Immunological & Biolog.Corp. announced that the 34th Annual General Meeting (AGM) o...

Read more

29 Nov 2023 10:47

News

Bharat Immunological & Biolog.Corp. to conduct AGM

Bharat Immunological & Biolog.Corp. announced that the 34th Annual General Meeting (AGM) o...

Read more

28 Nov 2023 18:37

Suven Pharmaceuticals Ltd News Hub

News

Cohance Lifesciences' API Unit-IV clears USFDA inspection

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the Unite...

Read more

26 May 2025 08:46

News

Suven Pharmaceuticals allots 12.80 cr equity shares

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value...

Read more

09 May 2025 09:58

News

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of Indi...

Read more

08 May 2025 09:39

News

Suven Pharmaceuticals receives regulatory nod for scheme of amalgamation

Suven Pharmaceuticals announced that it has received final approval from the Department of...

Read more

26 Apr 2025 12:56

News

Suven Pharmaceuticals to table results

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 M...

Read more

27 Mar 2025 09:42

News

Suven Pharmaceuticals receives credit ratings from CRISIL

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings...

Read more

28 Feb 2025 19:46

SWOT Analysis Of Bharat Immunological & Biological Corporation Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Bharat Immunological & Biological Corporation Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Suven Pharmaceuticals Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 110 Cr while Market cap of Suven Pharmaceuticals Ltd is 26,595 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd?

As of June 1, 2025, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹25.56. On the other hand, Suven Pharmaceuticals Ltd stock price is INR ₹1044.75.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Suven Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions